Clinical and hematological parameters associated with omalizumab response in chronic spontaneous urticaria
Authors:
- 7 September 2026
- journal article
- research article
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- p. 1-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Prevalence, Comorbidities, and Current Management of Chronic Spontaneous Urticaria in Japan: Retrospective Claims Database StudyThe Journal of Dermatology, 2025
- Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous UrticariaJAMA Dermatology, 2025
- Update on the Treatment of Chronic Spontaneous UrticariaDrugs, 2025
- New markers to predict the response to omalizumab in chronic spontaneous urticariaDermatologic Therapy, 2022
- The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticariaAllergy, 2021
- Clinical Activity of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Treatment-Refractory Chronic UrticariaJournal of Allergy and Clinical Immunology, 2020
- The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticariaCutaneous and Ocular Toxicology, 2018
- Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticariaThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticariaAllergy, 2016
- Co-Occurrence of Chronic Spontaneous Urticaria with Immunoglobulin A Deficiency and Autoimmune DiseasesInternational Archives of Allergy and Immunology, 2016